Orbital Therapeutics

Orbital Therapeutics was a Cambridge, Massachusetts biotechnology company developing next-generation RNA medicines, combining circular and linear RNA, targeted delivery, and AI-guided design across immunomodulation, in vivo CAR-T cell therapy, next-generation vaccines, and protein therapeutics. Its lead program, OTX-201, targeted autoimmune disease through B-cell depletion. Founded out of Beam Therapeutics and backed by ARCH Venture Partners, a16z Bio + Health, and Newpath Partners, the company raised a $270M Series A in 2023. In October 2025 Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion; orbitaltx.com now redirects to bms.com. As a therapeutics developer, Orbital publishes no public developer platform, API, or machine-readable API surface, so this record is an identity-only profile in the API Evangelist network.

Orbital Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, RNA Medicines, and Cell Therapy.

🌐 Visit website 📡 Source on GitHub

2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyBiotechnologyPharmaceuticalsRNA MedicinesCell TherapyLife SciencesCartVaccines

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 2.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 0.0 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/orbital-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Operate 1

Status, limits, changes, and where to get help

PressRelease

PressRelease

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: orbital-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/orbital-therapeutics.png
name: Orbital Therapeutics
description: Orbital Therapeutics was a Cambridge, Massachusetts biotechnology company developing next-generation RNA medicines,
  combining circular and linear RNA, targeted delivery, and AI-guided design across immunomodulation, in vivo CAR-T cell therapy,
  next-generation vaccines, and protein therapeutics. Its lead program, OTX-201, targeted autoimmune disease through B-cell
  depletion. Founded out of Beam Therapeutics and backed by ARCH Venture Partners, a16z Bio + Health, and Newpath Partners,
  the company raised a $270M Series A in 2023. In October 2025 Bristol Myers Squibb agreed to acquire Orbital Therapeutics
  for $1.5 billion; orbitaltx.com now redirects to bms.com. As a therapeutics developer, Orbital publishes no public developer
  platform, API, or machine-readable API surface, so this record is an identity-only profile in the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/orbital-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: Bristol Myers Squibb
x-acquired-announced: '2025-10-10'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- RNA Medicines
- Cell Therapy
- Life Sciences
- Cart
- Vaccines
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- RNA Medicines
- Cell Therapy
- Life Sciences
- CAR-T
- Vaccines
apis: []
common:
- type: Website
  url: https://www.orbitaltx.com/
- type: PressRelease
  name: BMS to Acquire Orbital Therapeutics
  url: https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics/default.aspx
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 0
  pass: local-v1